Search

Your search keyword '"Anthoney A"' showing total 131 results

Search Constraints

Start Over You searched for: Author "Anthoney A" Remove constraint Author: "Anthoney A" Topic medicine.medical_specialty Remove constraint Topic: medicine.medical_specialty
131 results on '"Anthoney A"'

Search Results

1. Pancreaticobiliary Malignancies in the Emergency Room: Management of Acute Complications and Oncological Emergencies

2. Early outcomes and complications following cardiac surgery in patients testing positive for coronavirus disease 2019: An international cohort study

3. Patients’ perspectives on factors facilitating adherence to tuberculosis treatment in Iquitos, Peru: a qualitative study

4. Outcomes after perioperative SARS-CoV-2 infection in patients with proximal femoral fractures: an international cohort study

5. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study

6. Delirium in the NICU: A Point Prevalence Study

7. Synthesis of Recommendations From 25 Countries and 31 Oncology Societies: How to Navigate Through Covid-19 Labyrinth

8. hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA

9. The Role of Continuing Perioperative Chemotherapy Post Surgery in Patients with Esophageal or Gastroesophageal Junction Adenocarcinoma: a Multicenter Cohort Study

10. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

11. Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma

12. Impact of a collaborative childhood anaemia intervention programme in Peru

13. Second-line FOLFOX chemotherapy for advanced biliary tract cancer – Authors' reply

14. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib

16. Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours

17. Patient and family support in the era of fake e-medicine: food for thought from an international consensus panel

18. Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma

19. FOLFOX as Second-Line Chemotherapy for Advanced Biliary Tract Cancer

20. A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma

21. ESPAC-4: A randomized controlled phase III trial of adjuvant gemcitabine (GEM) and capecitabine (CAP) versus gemcitabine in resected pancreatic ductal adenocarcinoma: five year follow up

25. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial

26. Resurgence of Vaccine-Preventable Disease: Ethics in the Pediatric Emergency Department

27. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study

28. A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine

29. The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma

31. The Prognostic Significance of the Hedgehog Signaling Pathway in Colorectal Cancer

32. Phase Ib/II study of elisidepsin in metastatic or advanced gastroesophageal cancer (IMAGE trial)

33. P-126 Markers of tumour inflammation are prognostic for overall survival in patients with advanced pancreatic ductal adenocarcinoma receiving FOLFIRINOX chemotherapy

34. ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma: Five year follow-up

35. Development of a combined paediatric emergency department and observation unit

37. Capecitabine and streptozocin ± cisplatin for gastroenteropancreatic neuroendocrine tumours: predictors of long-term survival in the NET01 trial

38. Predictive factors of thromboembolic complications in patients with esophagogatric adenocarcinoma undergoing preoperative chemotherapy

39. Effect of crizotinib on disease control in patient with advanced papillary renal cell carcinoma type 1 with MET mutations or amplification : Final results of EORTC 90101 CREATE

40. Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3 : European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'

41. Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer

42. Abstract P3-13-04: Efficacy and safety of eribulin in combination with capecitabine in patients with metastatic breast cancer: an open-label, phase II dose-confirmation study

43. Preventing malaria in the Peruvian Amazon: a qualitative study in Iquitos, Peru

44. Point-of-Care Ultrasound Diagnosis of Multiple Mandibular Fractures in an Adolescent Presenting to the Pediatric Emergency Department

45. A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO)

46. Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial

47. Optimal Duration and Timing of Adjuvant Chemotherapy After Definitive Surgery for Ductal Adenocarcinoma of the Pancreas: Ongoing Lessons From the ESPAC-3 Study

48. EP-1428: Early outcomes following neoadjuvant therapy for borderline resectable pancreatic cancer

49. ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy

50. Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’

Catalog

Books, media, physical & digital resources